Lilly's Cyramza succeeds in late-stage liver cancer trial


Eli Lilly and Co on Wednesday said its drug Cyramza met the main goal of helping patients live longer in a late-stage trial, which tested it as a potential treatment for the most common type of liver cancer. The drug was tested as a single therapy in a select population of liver cancer patients who were intolerant to, or worsened despite, treatment with Bayer AG's targeted cancer drug Nexavar.



from Biotech News